<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39337940</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>Vaccination Rates in Patients with Chronic Inflammatory Skin Diseases and Immunomodulatory Systemic Therapies-Vaccinations against SARS-CoV-2, Influenza Virus or Varicella Zoster Virus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1157</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life14091157</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The national guidelines and the Standing Committee on Vaccination (STIKO) of the Robert Koch Institute (RKI) in Germany support preventive vaccinations for patients under immunomodulatory treatments.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Retrospective analysis of data from patients with chronic inflammatory skin diseases from December 2021 to December 2022 with a focus on preventive vaccinations against influenza virus, varicella zoster virus, or SARS-CoV-2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with chronic inflammatory skin diseases were referred to our university outpatient's clinic for recommendations of systemic therapy. Vaccinations against influenza virus, varicella zoster virus, or SARS-CoV-2 were documented in 7365 analyzed patient files. A total of 79.7% were completely vaccinated against SARS-CoV-2, 49.7% patients were vaccinated against the influenza virus, and only 9.2% were completely vaccinated against varicella zoster virus.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">In our patients who came for counselling before or during systemic treatment, vaccination rates against SARS-CoV-2, varicella zoster virus, or influenza virus were low. Patients age 60 and above had higher rates than the average German population of the same age, but still no satisfying protection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We suggest informing patients about preventive vaccination before and during systemic immunomodulatory treatments and emphasize the need for active communication in this vulnerable patient group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-6127-3692</Identifier><AffiliationInfo><Affiliation>Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meineke</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Augustin</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorbe</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID</Keyword><Keyword MajorTopicYN="N">flu</Keyword><Keyword MajorTopicYN="N">immunocompromised</Keyword><Keyword MajorTopicYN="N">prevention</Keyword><Keyword MajorTopicYN="N">psoriasis</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword><Keyword MajorTopicYN="N">zoster</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. BST was Principal Investigator in vaccination studies with GSK as well, with no influence on this analysis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337940</ArticleId><ArticleId IdType="pmc">PMC11433363</ArticleId><ArticleId IdType="doi">10.3390/life14091157</ArticleId><ArticleId IdType="pii">life14091157</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atzeni F., Batticciotto A., Masala I.F., Talotta R., Benucci M., Sarzi-Puttini P. Infections and Biological Therapy in Patients with Rheumatic Diseases. Isr. Med. Assoc. J. 2016;18:164–167.</Citation><ArticleIdList><ArticleId IdType="pubmed">27228636</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabay C., Bel M., Combescure C., Ribi C., Meier S., Posfay-Barbe K., Grillet S., Seebach J.D., Kaiser L., Wunderli W., et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011;63:1486–1496. doi: 10.1002/art.30325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30325</ArticleId><ArticleId IdType="pubmed">21384334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner N., Assmus F., Arendt G., Baum E., Baumann U., Bogdan C., Burchard G., Föll D., Garbe E., Hecht J., et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62:494–515. doi: 10.1007/s00103-019-02905-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00103-019-02905-1</ArticleId><ArticleId IdType="pubmed">30899964</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkayam O. SP0158 Update of eular recommendations for vaccination of patients with autoimmune inflammatory rheumatic diseases; Proceedings of the Annual European Congress of Rheumatology, EULAR 2018; Amsterdam, The Netherlands. 13–16 June 2018; London, UK: Zurich, Switzerland: BMJ Publishing Group Ltd.; European League against Rheumatism; 2018. pp. 41.3–41.</Citation></Reference><Reference><Citation>Gelfand J.M., Armstrong A.W., Bell S., Anesi G.L., Blauvelt A., Calabrese C., Dommasch E.D., Feldman S.R., Gladman D., Kircik L., et al. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. J. Am. Acad. Dermatol. 2020;83:1704–1716. doi: 10.1016/j.jaad.2020.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.09.001</ArticleId><ArticleId IdType="pmc">PMC7471802</ArticleId><ArticleId IdType="pubmed">32891785</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert Koch-Institut . Wissenschaftliche Begründung zur Empfehlung einer Impfung mit dem Herpes Zoster-Subunit-Totimpfstoff. Robert Koch-Institut; Berlin, Germany: 2018.</Citation></Reference><Reference><Citation>Gisondi P., Facheris P., Dapavo P., Piaserico S., Conti A., Naldi L., Cazzaniga S., Malagoli P., Costanzo A. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: The Northern Italy experience. Br. J. Dermatol. 2020;183:373–374. doi: 10.1111/bjd.19158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.19158</ArticleId><ArticleId IdType="pmc">PMC7267283</ArticleId><ArticleId IdType="pubmed">32343839</ArticleId></ArticleIdList></Reference><Reference><Citation>Gresham L.M., Marzario B., Dutz J., Kirchhof M.G. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology. J. Am. Acad. Dermatol. 2021;84:1652–1666. doi: 10.1016/j.jaad.2021.01.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2021.01.047</ArticleId><ArticleId IdType="pmc">PMC7816618</ArticleId><ArticleId IdType="pubmed">33482251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebwohl M., Rivera-Oyola R., Murrell D.F. Should biologics for psoriasis be interrupted in the era of COVID-19? J. Am. Acad. Dermatol. 2020;82:1217–1218. doi: 10.1016/j.jaad.2020.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.03.031</ArticleId><ArticleId IdType="pmc">PMC7156810</ArticleId><ArticleId IdType="pubmed">32199889</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M., Reich K., Mrowietz U. Verfahrensweise bei der Systemtherapie von Patienten mit Psoriasis Während der Pandemischen Phase von SARS-CoV-2 (Coronavirus): Letter of Recommendations.  [(accessed on 21 December 2022)].  Available online:  https://www.bvdd.de/aktuelles-presse/newsroom/alle-nachrichten/details/empfehlungen-zu-systemtherapien-bei-schuppenflechte/</Citation></Reference><Reference><Citation>Radtke M.A., Schäfer I., Glaeske G., Jacobi A., Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J. Eur. Acad. Dermatol. Venereol. 2017;31:151–157. doi: 10.1111/jdv.13813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.13813</ArticleId><ArticleId IdType="pubmed">27521212</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieck T., Steffen A., Feig M., Siedler A. Impfquoten bei Erwachsenen in Deutschland—Aktuelles aus der KV-Impfsurveillance. Epid. Bull. 2021;50:3–22. doi: 10.25646/9436.</Citation><ArticleIdList><ArticleId IdType="doi">10.25646/9436</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert Koch-Institut (2024): COVID-19-Impfungen in Deutschland, Berlin: Zenodo.  [(accessed on 13 August 2024)].  Available online:  https://zenodo.org/records/12697471.</Citation></Reference><Reference><Citation>Lopez A., Mariette X., Bachelez H., Belot A., Bonnotte B., Hachulla E., Lahfa M., Lortholary O., Loulergue P., Paul S., et al. Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J. Autoimmun. 2017;80:10–27. doi: 10.1016/j.jaut.2017.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2017.03.011</ArticleId><ArticleId IdType="pubmed">28381345</ArticleId></ArticleIdList></Reference><Reference><Citation>Winthrop K.L., Mariette X., Silva J.T., Benamu E., Calabrese L.H., Dumusc A., Smolen J.S., Aguado J.M., Fernández-Ruiz M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Soluble immune effector molecules II: Agents targeting interleukins, immunoglobulins and complement factors) Clin. Microbiol. Infect. 2018;24((Suppl. S2)):S21–S40. doi: 10.1016/j.cmi.2018.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2018.02.002</ArticleId><ArticleId IdType="pubmed">29447987</ArticleId></ArticleIdList></Reference><Reference><Citation>Vygen-Bonnet S., Schlaberg J., Koch J. Rolle, Arbeitsweise und Empfehlungen der Ständigen Impfkommission (STIKO) im Kontext der COVID-19-Pandemie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022;65:1251–1261. doi: 10.1007/s00103-022-03610-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00103-022-03610-2</ArticleId><ArticleId IdType="pmc">PMC9684750</ArticleId><ArticleId IdType="pubmed">36416888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hmamouchi I., Winthrop K., Launay O., Dougados M. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: Data from the international COMORA cohort. Vaccine. 2015;33:1446–1452. doi: 10.1016/j.vaccine.2015.01.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.01.065</ArticleId><ArticleId IdType="pubmed">25659279</ArticleId></ArticleIdList></Reference><Reference><Citation>Loubet P., Kernéis S., Groh M., Loulergue P., Blanche P., Verger P., Launay O. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine. 2015;33:3703–3708. doi: 10.1016/j.vaccine.2015.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.06.012</ArticleId><ArticleId IdType="pubmed">26073016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri M., Dixon W.G. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2015;29:290–305. doi: 10.1016/j.berh.2015.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2015.05.009</ArticleId><ArticleId IdType="pubmed">26362745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling J., Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Rev. Vaccines. 2016;15:239–256. doi: 10.1586/14760584.2016.1115351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1115351</ArticleId><ArticleId IdType="pubmed">26642867</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra F., Lo E., Kalashnikov V., Richardson K. Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infect. Dis. 2016;3:ofw205. doi: 10.1093/ofid/ofw205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofw205</ArticleId><ArticleId IdType="pmc">PMC5144657</ArticleId><ArticleId IdType="pubmed">27942537</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran C.T., Ducancelle A., Masson C., Lunel-Fabiani F. Herpes zoster: Risk and prevention during immunomodulating therapy. Jt. Bone Spine. 2017;84:21–27. doi: 10.1016/j.jbspin.2016.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2016.04.001</ArticleId><ArticleId IdType="pubmed">27245419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>